Latest ACRP-CP Pass Guaranteed Exam Dumps with Accurate & Updated Questions
ACRP-CP Exam Brain Dumps - Study Notes and Theory
NEW QUESTION # 62
The process of ensuring and documenting that an electronic data processing system conforms to the sponsor's established requirements for completeness, accuracy, reliability, and consistent intended performance is called:
- A. Validation
- B. Quality Control
- C. Quality Assurance
- D. Programming
Answer: A
Explanation:
Validation is the process of ensuring that an electronic data processing system meets the sponsor's specifications for completeness, accuracy, reliability, and consistent performance. It involves systematic testing and documentation to demonstrate that the system functions as intended, especially in the context of capturing, processing, and managing clinical trial data.
GCP guidelines specify that validation of electronic systems is crucial to maintain data integrity and compliance with regulatory standards.
"Validation ensures that electronic data systems function according to the sponsor's requirements, maintaining data accuracy and reliability." Objectives:
Maintain data integrity and reliability.
Demonstrate system compliance with regulatory requirements.
NEW QUESTION # 63
SAEs must be reported immediately by the site to the:
- A. Regulatory agency.
- B. DSMB/IDMC.
- C. Sponsor.
- D. IRB/IEC.
Answer: C
Explanation:
Serious Adverse Events (SAEs) must be reported immediately to the sponsor. The sponsor then assesses the severity, causality, and potential impact on the study and decides whether further reporting to regulatory authorities and IRB/IEC is required. Immediate reporting ensures that appropriate actions are taken to safeguard participant safety.
GCP guidelines specify that the site must notify the sponsor immediately about any SAE to ensure timely safety assessment and reporting.
"Sites must report all serious adverse events immediately to the sponsor, who will then determine the appropriate regulatory and ethical reporting requirements." Objectives:
* Ensure rapid reporting of serious adverse events.
* Maintain safety monitoring during the trial.
NEW QUESTION # 64
Which of the following is a conflict of interest for a PI conducting a study?
- A. A PI that presents at an investigator meeting
- B. A PI who is a key opinion leader, writes the protocol
- C. A PI who receives payment for the study
- D. A PI that votes on the IRB/IEC approval of the protocol
Answer: D
Explanation:
A Principal Investigator (PI) who is involved in voting on the IRB/IEC approval of their own protocol is considered to have a conflict of interest. The IRB/IEC must be independent and impartial when reviewing research proposals. Allowing the PI to vote on their own study compromises the ethical review process. To maintain unbiased decision-making, PIs must recuse themselves from such votes.
GCP guidelines emphasize the importance of avoiding conflicts of interest in the IRB/IEC decision-making process to maintain objectivity and ethical standards.
"A PI should not participate in voting or decision-making processes regarding the approval of their own study to avoid conflicts of interest." Objectives:
* Maintain impartiality in ethical review.
* Prevent conflicts of interest during IRB/IEC processes.
NEW QUESTION # 65
Preliminary evidence suggests a low-dose anti-cancer drug given for a short period of time may reduce the risk of developing cancer in patients who are at increased risk for developing cancer. The drug has potentially serious side effects. What is the MOST important question to consider before designing a clinical trial to test this hypothesis?
- A. How effective is the drug at treating patients that have been previously diagnosed with cancer?
- B. How likely are patients at high risk of cancer going to develop cancer during the study?
- C. How willing are current patients to participate in a trial with potentially serious side effects?
- D. How does the risk of developing cancer compare to the anticipated side effects from the drug?
Answer: D
Explanation:
Before initiating a clinical trial with a drug that has potentially serious side effects, it is essential to evaluate the risk-benefit ratio. The primary consideration is whether the potential benefits (reduced cancer risk) outweigh the risks (serious side effects). This assessment is fundamental to ethical clinical trial design.
The answer is verified as per GCP and ethical guidelines, which require a thorough assessment of risk versus benefit before conducting human trials.
"An assessment of potential benefits versus risks is a fundamental principle in the ethical design of clinical trials, especially when potential adverse effects are severe." Objectives:
* Ensure ethical considerations in trial design.
* Assess the potential harm versus benefit to participants.
NEW QUESTION # 66
When assessing the monitoring needs for a study, sponsors should:
- A. Ensure monitoring visits are conducted at periodic intervals with a minimum of monthly monitoring visits.
- B. Permit PIs to select a monitor for their site as long as they are independent of the PI.
- C. Ensure monitors have the scientific and/or clinical knowledge needed to monitor the trial adequately.
- D. Use central monitoring instead of conducting physical monitoring visits at sites.
Answer: C
Explanation:
Sponsors must ensure that monitors are adequately qualified, possessing the necessary scientific and clinical knowledge to effectively oversee the trial. This ensures that monitors can accurately assess protocol compliance, data integrity, and participant safety. The quality of monitoring directly impacts the credibility of the trial outcomes.
GCP guidelines specify that monitors must be adequately trained and knowledgeable about the trial protocol, investigational product (IP), and clinical research standards.
"The sponsor must ensure that monitors have appropriate qualifications and training to conduct effective trial monitoring." Objectives:
* Maintain data integrity through skilled monitoring.
* Ensure patient safety and protocol compliance.
NEW QUESTION # 67
Per the protocol, participants' blood creatinine level must be no greater than 2.5 times the upper limit of normal (0.7-1.2 mg/dL). What is the maximum creatinine level the participant can have and be eligible for the trial?
- A. 2.6 mg/dL
- B. 3.6 mg/dL
- C. 1.8 mg/dL
- D. 3.0 mg/dL
Answer: D
Explanation:
To calculate the maximum allowable creatinine level, multiply the upper limit of normal (1.2 mg/dL) by 2.5.
1.2 x 2.5 = 3.0 mg/dL
Therefore, the maximum creatinine level that a participant can have to remain eligible for the trial is 3.0 mg
/dL.
GCP guidelines specify that eligibility criteria, including lab values, must be strictly followed to maintain protocol compliance.
"The protocol specifies that laboratory values must not exceed the defined limits to ensure participant safety and data integrity." Objectives:
* Maintain accurate interpretation of laboratory criteria.
* Ensure compliance with protocol-defined inclusion/exclusion criteria.
NEW QUESTION # 68
Source data/documentation should be:
- A. Attributable, legible, contemporaneous, original, accurate, and clear.
- B. Attributable, legible, correct, original, accurate, and clear.
- C. Attributable, legible, contemporaneous, original, accurate, and complete.
- D. Attributable, legible, correct, original, accurate, and complete.
Answer: C
Explanation:
Source data/documentation in clinical trials must meet the ALCOA-C standard: Attributable, Legible, Contemporaneous, Original, Accurate, and Complete. This ensures that data is credible, traceable to the source, and maintains integrity throughout the study. These attributes are essential for maintaining high- quality, reliable, and verifiable clinical trial records.
GCP guidelines mandate that source documentation should adhere to the ALCOA-C principles to maintain data integrity and reliability.
"Source data must be attributable, legible, contemporaneous, original, accurate, and complete to meet quality and compliance standards." Objectives:
* Maintain data integrity and reliability.
* Adhere to best practices in clinical documentation.
NEW QUESTION # 69
Which document confirms the PI's agreement to permit auditing at the study site?
- A. ICF
- B. IB
- C. Protocol
- D. Delegation Log
Answer: A
Explanation:
The Informed Consent Form (ICF) typically includes a statement indicating that the participant's records may be reviewed by monitors, auditors, and regulatory authorities. This ensures transparency and compliance with regulatory requirements, allowing for audits and inspections when necessary.
This answer follows GCP guidelines which specify that the ICF should include consent for audits and inspections to protect subject confidentiality while ensuring data integrity.
"The ICF must include a statement allowing access to trial data for monitoring, auditing, and regulatory inspection purposes." Objectives:
* Ensure informed consent for data access.
* Facilitate compliance with auditing requirements.
NEW QUESTION # 70
Who is responsible for submitting a protocol amendment to the IRB/IEC?
- A. Investigator
- B. CRC
- C. Sponsor
- D. CRA
Answer: A
Explanation:
The investigator holds the responsibility for submitting any protocol amendments to the IRB/IEC for review and approval. This step ensures that all changes are ethically evaluated before being implemented, maintaining compliance with regulatory requirements.
According to GCP guidelines, the investigator must submit protocol changes to the IRB/IEC to secure approval before making any modifications to the study.
"The investigator must inform the IRB/IEC of any proposed protocol changes and secure approval prior to implementation." Objectives:
* Maintain ethical oversight in study modifications.
* Adhere to regulatory submission requirements.
NEW QUESTION # 71
A PI on a study is a regular member of the IRB/IEC. Which of the following statements is TRUE regarding their participation in the IRB/IEC discussion and deliberation?
- A. They cannot be the PI on the clinical study due to conflict of interest.
- B. They must recuse themselves from the meeting given their dual roles as IRB/IEC member and PI.
- C. They can attend the meeting and can vote/provide opinion on whether to approve the study.
- D. They can attend the meeting, but should not vote/provide opinion on whether to approve the study.
Answer: B
Explanation:
If a PI is also a member of the IRB/IEC, they must recuse themselves from the meeting when their own study is being reviewed to avoid conflicts of interest. This practice preserves the objectivity and impartiality of the IRB/IEC's decisions.
The answer is verified based on IRB/IEC operational guidelines, which mandate that members with potential conflicts recuse themselves from discussions and voting.
"To maintain objectivity, IRB/IEC members who have a conflict of interest related to a study must recuse themselves from the review and decision-making process." Objectives:
* Maintain impartiality in IRB/IEC decisions
* Prevent conflicts of interest in clinical trial approval
NEW QUESTION # 72
Which of the following should be considered when implementing a risk-based monitoring plan?
- A. Monitoring schedule must be pre-defined in the monitoring plan.
- B. On-site monitoring frequency may change depending on the quality of the data.
- C. 100% source document review is mandatory.
- D. Centralized monitoring must be incorporated in any trials.
Answer: B
Explanation:
Risk-based monitoring focuses on adapting the frequency and intensity of on-site visits based on data quality and site performance. If the data is consistently accurate and reliable, the monitoring frequency may be reduced. Conversely, if issues are identified, more frequent monitoring may be necessary.
GCP guidelines emphasize a flexible approach to monitoring, allowing adjustments based on the risk profile and quality of data collected.
"Risk-based monitoring involves adapting the frequency of on-site visits according to the quality of the data and the site's compliance level." Objectives:
* Implement a dynamic monitoring strategy.
* Enhance efficiency while maintaining data integrity.
NEW QUESTION # 73
A site has reported multiple temperature excursions for an IP, primarily because the air conditioning (A/C) gets shut off after business hours. A separate A/C unit cannot be installed in the room where the IP is kept.
What would be the MOST effective long-term mitigation strategy?
- A. Install an air cooler requiring regular water refills to maintain the room temperature.
- B. Return all IP and request the CRO/Sponsor to directly ship IP to participants.
- C. Continue reporting temperature excursions per the pharmacy manual guidelines.
- D. Invest in a room temperature controlled IP cabinet and transfer IP to this unit.
Answer: D
Explanation:
Investing in a temperature-controlled IP cabinet is the most effective and sustainable solution for maintaining IP stability. This cabinet can consistently regulate temperature without relying on external A/C systems, thereby minimizing the risk of excursions and ensuring compliance with storage requirements.
GCP guidelines state that IP must be stored under controlled conditions as specified by the protocol and product labeling.
"Temperature-controlled storage units should be used when site environmental conditions are not reliable to maintain IP stability." Objectives:
* Ensure IP stability and compliance.
* Mitigate temperature excursion risks effectively.
NEW QUESTION # 74
The sponsor should supply a PI with the IP after:
- A. Approval of protocol by the PI.
- B. Approval/favorable opinion from IRB/IEC and regulatory authority.
- C. Approval of protocol by the sponsor.
- D. Submission of documents to IRB/IEC and regulatory authority for review.
Answer: B
Explanation:
The sponsor may only provide the investigational product (IP) after the IRB/IEC and relevant regulatory authorities have approved the protocol. This ensures that the trial complies with ethical and legal standards before initiating IP administration.
According to GCP guidelines, sponsors must wait for all necessary approvals before distributing IP to the trial site.
"The investigational product may only be supplied after obtaining regulatory and IRB/IEC approval to ensure ethical conduct of the trial." Objectives:
* Ensure regulatory compliance before initiating IP distribution.
* Protect participant safety and ethical standards.
NEW QUESTION # 75
An investigator in a multicenter trial reports multiple occurrences of an SAE to the sponsor. Who is responsible for reporting the SAEs to the remaining sites' IRB/IECs?
- A. Investigator at each site
- B. Regulatory authority
- C. Study sponsor
- D. Original reporting investigator
Answer: C
Explanation:
The study sponsor is responsible for disseminating information about SAEs to all participating sites. This ensures consistent and timely communication of safety concerns, allowing each site to take appropriate actions in line with local regulations and IRB/IEC requirements.
The answer aligns with ICH E6(R2) GCP guidelines which mandate the sponsor to communicatesafety information to all investigators and sites involved in a multicenter trial.
"The sponsor must inform all investigators of safety information that could affect the conduct of the trial or the safety of subjects." Objectives:
* Maintain consistent safety reporting across all trial sites.
* Ensure regulatory compliance in multicenter trials.
NEW QUESTION # 76
Which of the following statements is TRUE about an EDC system?
- A. There should be an audit trail to track data entries, deletions, and changes.
- B. The eCRF should be an exact page-by-page replica of the paper CRF.
- C. A separate workstation should be made available for the monitor.
- D. IRB/IEC approval is required before the use of the computerized system.
Answer: A
Explanation:
An Electronic Data Capture (EDC) system must include an audit trail to ensure data integrity. This audit trail records every data entry, modification, and deletion along with timestamps and user identification. It is a critical feature for maintaining traceability and accountability in clinical research, allowing for the reconstruction of data changes and ensuring compliance with Good Clinical Practice (GCP).
GCP guidelines mandate that electronic data systems used in clinical trials must maintain an audit trail to ensure data integrity and traceability.
"An audit trail is essential in an EDC system to document all data entries, changes, and deletions to maintain data integrity." Objectives:
* Ensure data integrity through traceable record-keeping.
* Maintain compliance with regulatory standards.
NEW QUESTION # 77
Which of the following elements of the Informed Consent are NOT required?
- A. A description of potential benefits
- B. Statement that study involves research
- C. A description of any reasonably foreseeable risks or discomforts
- D. Subject legal rights can be waived
Answer: D
Explanation:
Informed consent must not include any language that implies a waiver of the participant's legal rights or releases the investigator, sponsor, or institution from liability for negligence. Such language violates ethical standards and the principles of voluntary participation.
According to GCP guidelines and ethical principles, the informed consent document must not include any clause that waives a participant's legal rights.
"An informed consent form must not include language that waives the participant's legal rights or releases the sponsor or investigator from liability." Objectives:
* Protect participant rights in clinical trials.
* Ensure that consent is given voluntarily and ethically.
NEW QUESTION # 78
A clinical trial where participants will be randomized to receive a sequence of two medications has which design configuration?
- A. Group sequential
- B. Factorial
- C. Parallel Group
- D. Crossover
Answer: D
Explanation:
A crossover study design involves participants receiving multiple interventions sequentially, with a washout period in between to minimize carryover effects. This design allows each participant to serve as their own control, increasing statistical power while reducing variability. It is commonly used when comparing two treatments or interventions.
GCP guidelines classify a crossover design as one where subjects receive multiple treatments in a specified sequence.
"In crossover trials, participants receive each intervention in a specific order, allowing for within-subject comparison." Objectives:
* Understand the structure of crossover studies.
* Improve statistical efficiency through self-control comparisons.
NEW QUESTION # 79
An impartial witness should be present during the entire informed consent discussion when:
- A. An interpreter is translating the consent form for a subject.
- B. A parent/guardian is consenting for a minor subject.
- C. A subject has been determined to be vulnerable.
- D. A legally acceptable representative is unable to read.
Answer: D
Explanation:
An impartial witness is required when a legally acceptable representative (LAR) or the subject themselves cannot read. The witness ensures that the information is presented accurately and that the consent process is conducted ethically. The witness also signs the consent form to confirm that the subject or representative understands the study details.
GCP guidelines require an impartial witness to be present to confirm that the consent information is correctly conveyed and understood when the subject or LAR cannot read.
"An impartial witness is required when the subject or legally acceptable representative is unable to read, ensuring the consent process is transparent and ethically sound." Objectives:
* Protect the rights of individuals with literacy challenges.
* Maintain ethical standards in the consent process.
NEW QUESTION # 80
......
Pass ACRP ACRP-CP Test Practice Test Questions Exam Dumps: https://www.actualpdf.com/ACRP-CP_exam-dumps.html
The Best ACRP Certified Professional Study Guide for the ACRP-CP Exam: https://drive.google.com/open?id=10utzVabWjLqRgo0vUHoTPLIcxHqIlk8k
